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http:WHAT THIS PAPER ADDS
Performing carotid endarterectomy within the hyperacute period after a transient ischaemic attack or minor
stroke (whether this time period was deﬁned as <48 hours, <7 days, or <14 days) was not associated with a
signiﬁcant increase in the procedural risk.Objectives: There have been concerns that performing carotid endarterectomy (CEA) in the hyperacute period
after onset of a transient ischaemic attack (TIA) or stroke may be associated with a signiﬁcant increase in the
procedural risk that could offset any long-term beneﬁt to the patient. The aim of this audit was to determine the
30-day risk of stroke/death after CEA in symptomatic patients, stratiﬁed for delay from the most recent
neurological event, mode of presentation, and age.
Methods: Retrospective audit in 475 recently symptomatic patients between October 1, 2008, and April 24,
2013.
Results: Forty-one patients (9%) underwent surgery<48hours of theirmost recent event,with a 30-day death/stroke
rate of 2.4% (1/41). The procedural risk was 1.8% in 167 patients who underwent surgery within 3e7 days (3/167),
falling to 0.8% in 133 patientswho underwent surgery between 8 and 14 days (1/133) and 0.8% in 134 patients whose
surgery took place after>14 days had elapsed (1/134). Overall, 208 (44%) underwent surgery within 7 days of their
most recent neurological event (30-day risk ¼ 1.9%), while 341 (72%) underwent CEA within 14 days (30 day
risk ¼ 1.5%). There was no evidence of any systematic differences in procedural risk by operating in the hyperacute
period relating to mode of presentation (TIA, stroke, amaurosis) or age (<80 years; >80 years).
Conclusions: This audit found no evidence that the procedural risk was increased when CEA was performed in
the hyperacute period whether this time period was deﬁned as <48 hours, <7 days, or <14 days.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The move towards performing carotid endarterectomy
(CEA) as soon as possible after onset of symptoms has been
driven by awareness that the early risk of stroke after
suffering a transient ischaemic attack (TIA) is very much
higher than previously thought.1 Recent evidence suggests
that even following rapid introduction of best medical
therapy, TIA/stroke patients with a 50e99% stenosis face a
5% risk of stroke at 48 hours, which increases to 8% at 7
days and 11% at 14 days.2
However, some surgeons have expressed concerns that
the move towards expedited CEA may be associated with a
signiﬁcant increase in the procedural risk that could negaterresponding author. A.R. Naylor, Vascular Research Group, Division of
ascular Sciences, Clinical Sciences Building, Leicester Royal Inﬁrmary,
er LE27LX, UK.
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//dx.doi.org/10.1016/j.ejvs.2013.08.014any long-term beneﬁt to the patient.3 This dilemma was
amply illustrated in the 2012 SwedVasc Audit, which re-
ported an 11.5% death/stroke rate if CEA was performed
within 48 hours of the index event.4
In Leicester, a (daily) rapid access TIA clinic was estab-
lished in October 2008 and any patient found to have an
ipsilateral 50e99% stenosis (using the North American
Symptomatic Carotid Endarterectomy Tril [NASCET] mea-
surement method) was transferred directly to the Vascular
Unit for expedited CEA.5 The current audit was undertaken,
in light of the 2012 SwedVasc Report, to establish whether
treatment in the hyperacute period (whether this was
deﬁned as <48 hours, <7 days, or <14 days) was associ-
ated with a signiﬁcant increase in procedural risk.MATERIALS AND METHODS
Between October 1, 2008, and April 24, 2013, 541 patients
underwent CEA in the Leicester Vascular Unit. Of these, 66
(12%) were neurologically asymptomatic and excluded from
520 R. Sharpe et al.the current audit, which was restricted to the 475 patients
who had reported recent carotid territory symptoms.
The aim was to determine whether expedited CEA was
associated with increased procedural risks in the immediate
period after the most recent neurological event (48 hours,
3e7 days, 8e14 days, >14 days). The Leicestershire,
Northamptonshire and Rutland Research Ethics Committee
advised that this study did not fall under the remit of the
NHS Research Ethics Committee, as it was audit/service
evaluation.
Preoperative assessment
On October 1, 2008, a daily “Rapid Access TIA Clinic” was
established, enabling a specialist consultant in stroke med-
icine to see patients as soon as possible after onset of
symptoms.5 The clinic offers single-visit computed tomog-
raphy (CT)/functional magnetic resonance imaging (MRI)
and colour duplex ultrasound assessment of the extracranial
vessels. All patients undergo risk factor assessment and
“best medical therapy” is started in the clinic. Patients
found to have an ipsilateral 50e99% stenosis are trans-
ferred directly to the Surgical Admissions Unit for expedited
CEA, unless contraindicated.
Medical therapy
In Leicestershire, considerable efforts have been made to
increase public awareness about the need to seek urgent
medical advice should anyone suffer symptoms that might
be attributable to a TIA/minor stroke.6 The referring family
doctor or Emergency Department submits an electronic
referral to the TIA Clinic (which includes an ABCD2 score7)
and the referring doctor is then responsible for ensuring
that the patient is started on 300 mg of aspirin and 40 mg
of simvastatin before referral. These medications are then
continued until the patient is seen in the TIA Clinic. Patients
with an ABCD2 score of 0e3 are seen within 7 days of
referral, while those with an ABCD2 score of 4e7 are seen
the same day or the following morning. Provided an intra-
cranial haemorrhage is excluded in the TIA clinic (CT/MRI), a
further 300 mg of aspirin and 40 mg of simvastatin is given
to the patient. Patients who suffered a TIA or a non-
disabling stroke (deﬁned as a Rankin score8 of 0e2) and
who were found to have an ipsilateral 50e99% stenosis are
transferred to the Surgical Assessment Unit (SAU) for
expedited CEA. In between admission to the SAU and un-
dergoing CEA, each patient received 75 mg of aspirin and
40 mg of simvastatin daily, in addition to any other pre-
scribed risk factor medications. On the night prior to sur-
gery, a single 75-mg dose of clopidogrel was administered
to the patient, in addition to their regular aspirin.8 A very
small number of patients admitted with crescendo TIAs
(<10 during this time period) were treated with intrave-
nous heparin in between SAU admission and undergoing
CEA. No other patient received adjuvant heparin therapy.
Patients who were admitted to the Stroke Unit with a
disabling stroke (deﬁned as a Rankin score 3) and who
had a 50e99% stenosis and who then made a rapidrecovery (either spontaneously or following thrombolysis)
underwent surgery on the next available theatre list. Pa-
tients presenting with a disabling stroke (in whom there
was no early improvement) had their surgery deferred for
2e4 weeks and/or until their Rankin score reduced to 2.
The rare exception was the occasional patient with a
disabling stroke who suffered recurrent symptoms (despite
best medical therapy) and who then underwent expedited
surgery.
Operation
The operative procedure has remained essentially un-
changed since 1992 (general anaesthesia, routine patching
(polyester from 2008e2011; bovine pericardial patch
2012e2013), routine shunting (Pruitt Inahara), systemic
heparinization (5,000 units intravenous unfractionated) and
distal intimal tacking sutures). In patients with an accessible
transtemporal window, transcranial Doppler (TCD) moni-
toring was commenced following induction of anaesthesia
using a ﬁxed 2-MHz head probe, which was protected by a
semi-circular metal headguard.9 The surgeon and anaes-
thetist aimed to ensure that mean blood ﬂow velocity in the
middle cerebral artery (MCAV) was >15 cm/second at all
times. If the MCAV was <15 cm/sec following shunt
insertion, the shunt was repositioned to exclude abutment
against the distal internal carotid artery (ICA) lumen. If the
MCAV remained <15 cm/sec, blood pressure was thera-
peutically elevated by the anaesthetist. Immediately prior
to patch closure, a 5-mm space was retained adjacent to
the oriﬁce of the external carotid artery. The shunt was
removed and all vessels were back vented and irrigated
with heparinized saline. The lumen of the endarterectomy
zone was then inspected with a ﬂexible hysteroscope
(Olympus 1070-48). Our policy was to repair all intimal ﬂaps
>3 mm and to remove any residual thrombus from the
lumen.10
Postoperative monitoring and neurological events
Between October 1, 2008, and July 31, 2009, CEA patients
underwent postoperative TCD monitoring to identify the
small cohort of patients with high-rate embolization (who
are known to be high-risk of progressing to thrombotic
stroke) and who were administered dextran.8 However, TCD
monitoring and selective Dextran therapy was abandoned
on 1 August 2009 following a 3-year audit, which showed
that peri-operative dual antiplatelet protocol (daily aspirin
plus clopidogrel the night before surgery) virtually abolished
postoperative embolization and thromboembolic stroke.11
All patients were monitored after surgery in the Recovery
Area of theatre for 3 hours before transfer back to the
Vascular Ward, unless there were problems with post-CEA
hypertension. Since January 2008, every CEA patient has
had written guidance for managing post-CEA hypertension
placed in their case notes so that these were immediately
available should the need for treatment arise.9
Patients who recovered from anaesthesia with a new
neurological deﬁcit (which persisted for >24 hours) were
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who recovered from anaesthesia with no new neurological
deﬁcit, but who then suffered a neurological deﬁcit lasting
>24 hours (within 30 days of surgery) were deﬁned as
having suffered a postoperative stroke. Anyone suffering a
peri-operative stroke underwent a battery of investigations
including CT angiography, Duplex ultrasound, and TCD in
order to determine the most likely aetiology.9Follow-up
All patients were scheduled to return for surgical outpatient
review between 4 and 6 weeks after surgery. Most patients
were also seen by their referring Stroke Physician in a
separate outpatient setting. A very small minority who
declined to return for formal review (usually because
considerable travel was involved) were followed up by
telephone contact to both the GP and patient.
RESULTS
Between October 1, 2008, and April 15, 2013, 475 CEAs
were performed in recently symptomatic patients. Two
hundred and seventy-two patients (57%) presented with a
TIA, 94 (20%) with amaurosis, and 109 (23%) presented
with a stroke. Patient comorbidities included treated hy-
pertension (n ¼ 342, 72%), angina (n ¼ 70, 15%), previous
myocardial infarction (n ¼ 60, 13%), diabetes (n ¼ 103,
22%), and active smoking 19%).
There were six deaths and/or strokes within 30 days of
surgery (1.3%) and the most likely aetiologies are detailed in
Table 1. Two recovered from anaesthesia with a new, ipsi-
lateral neurological deﬁcit that was considered to be sec-
ondary to intraoperative haemodynamic failure (both non-
disabling at 30 days). The ﬁrst (IOH1) had no retrograde
backﬂow following removal of the shunt and an on-table
angiogram revealed a pinhole stenosis in the distal ICA,
which had not been identiﬁed on preoperative imaging.
Transcranial Doppler had been used and it is assumed that
the wrong vessel (probably the posterior cerebral) was
insonated, which led the surgeon to think that cerebralTable 1. Aetiology, laterality, severity and timing of peri-operative stro
Initial presenting
symptom
Peri-operative stroke Probable aetio
Timing Ipsilateral or
contralateral
Non disabling stroke Intraoperative Ipsilateral Presumed hae
missed critical
monitoring PC
Disabling stroke Intraoperative Ipsilateral Presumed hae
shunt. extende
No TCD windo
Transient ischaemic
attack
Day 1 Contralateral New ischaemic
occlusion
Transient ischaemic
attack
Day 2 Contralateral New ischaemic
Non disabling stroke Day 5 Ipsilateral Intracranial ha
TIA Day 24 Contralateral New ischaemic
and in atrial ﬁperfusion was adequate. The patient with the second
intraoperative stroke (IOH2) had no acoustic window for
TCD. He had suffered a disabling stroke (Rankin 3) and
required expedited surgery because of recurrent symptoms
despite medical therapy. His distal ICA was too small to
insert a Pruitt shunt and he extended his pre-existing
neurological deﬁcit. By 30 days, however, his Rankin score
had reduced to 1.
There were three non-disabling, postoperative strokes
(Rankin 0e2) affecting the contralateral hemisphere. One
occurred in a patient with a pre-existing contralateral oc-
clusion (CIS1), the second had a 65% contralateral stenosis
(CIS2), while the third patient (CIS3) was readmitted on day
24 with a contralateral ischaemic stroke (25% ICA stenosis),
but was also found to be in atrial ﬁbrillation. He was treated
by anticoagulation. The sixth patient (ICH) suffered a fatal
intracranial haemorrhage on day 5.
The 30-day death/stroke rate in patients presenting with
amaurosis was 0% (0/94), increasing to 1.1% in patients
presenting with a TIA (3/272) and 2.8% in patients pre-
senting with a stroke (3/109). Forty-one patients (9%) un-
derwent surgery <48 hours of their most recent event,
incurring a 30-day death/stroke rate of 2.4% (1/41). The
procedural risk was 1.8% in 167 patients who underwent
surgery within 3e7 days of suffering their most recent
neurological event (3/167), falling to 0.8% in 133 patients
who underwent surgery between 8e14 days after the most
recent event (1/133) and 0.8% in 134 patients whose sur-
gery took place after>14 days had elapsed (1/134). Overall,
208 (44%) underwent surgery within 7 days of their most
recent neurological event, while 341 (72%) underwent CEA
within 14 days.
Table 2 details the 30-day risk of death/stroke stratiﬁed
for delay from the most recent cerebral event and the initial
presenting symptom. There was no evidence of any sys-
tematic difference in procedural risk according to mode of
presentation or by performing surgery in the very early time
period after the most recent symptom. Table 3 presents
similar data for the 30-day risk of death/stroke, stratiﬁed
for delay from the most recent cerebral event and age.kes/deaths.
logy of peri-operative stroke Outcome
at 30 days
Code for
Tables 2 and 3
modynamic: pre-op imaging
distal ICA stenosis. TCD probably
A
Rankin 0 IOH1
modynamic: unable to insert
d pre-existing neurological deﬁcit.
w
Rankin 1 IOH2
infarct on CT: known contralateral Rankin 1 CIS1
infarct on CT: 65% ICA stenosis Rankin 1 CIS2
emorrhage Died ICH
infarct on CT: 40% ICA stenosis
brillation
Rankin 0 CIS3
Table 2. Thirty-day death/stroke in 475 symptomatic patients undergoing carotid endarterectomy: stratiﬁed for delay to surgery and index
presenting symptom.
30-day death/stroke Delay from most recent cerebral event Overall
<2 days 3e7 days 8e14 days >14 days
Patients referred with amaurosis 0/10 (0%) 0/16 (0%) 0/29 (0%) 0/39 (0%) 0/94 (0%)
Patients referred with a TIA 1/28 (3.6%)CIS1 1/112 (0.9%)CIS3 0/68 (0%) 1/64 (1.6%)CIS2 3/272 (1.1%)
Patients referred with a stroke 0/3 (0%) 2/39 (5.1%)10H1þ2 1/36 (2.8%)ICH 0/31 (0%) 3/109 (2.8%)
Overall 1/41 (2.4%) 3/167 (1.8%) 1/133 (0.8%) 1/134 (0.8%) 6/475 (1.3%)
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procedural risk relating to the patient’s age and no evidence
that elderly patients who underwent CEA within the ﬁrst
few days of their most recent symptom incurred a signiﬁ-
cantly higher procedural risk.DISCUSSION
The drive towards performing expedited CEA in recently
symptomatic patients is based upon awareness that the
highest risk period for recurrent stroke is the ﬁrst few days
after onset of symptoms1,2,12,13 as well as evidence from
the landmark randomized trials that CEA confers maximum
beneﬁt if performed as soon as possible after onset of
symptoms.14
NICE15 has recommended that CEA be performed within
14 days of symptom onset (wherever possible) and the
14-day threshold was also adopted in the 2009 European
Society of Vascular Surgery Guidelines.16 By contrast, the
2011 American Heart Association Guidelines simply advised
clinicians that intervening within 14 days was a “reason-
able” option unless contraindicated.17 In the UK, the Na-
tional strategy for stroke has adopted an even more
aggressive approach and has recommended that, by 2017,
symptomatic patients should undergo CEA <48 hours of
symptom onset.18 The latter recommendation (currently
more aspiration than reality) has attracted a lot of
comment, partly because there seemed to be relatively
little evidence supporting the 48-hour threshold.
However, a number of recent natural history studies now
suggest that symptomatic patients with a NASCET 50e99%
ICA stenosis do face a very high risk of stroke within the ﬁrst
7 days after onset of symptoms (Table 4). In 2007, Purroy
et al.13 reported a 10% risk of stroke at 7 days in patients
with an ipsilateral 50e99% carotid stenosis. In 2009, a
Spanish group reported a 17% risk of stroke at 72 hours,
increasing to 22% at 7 days.1 In 2013, a Swedish group (who
implemented best medical therapy as soon as possible after
onset of symptoms) still observed a 5% risk of stroke at 48Table 3. Thirty-day risk of death/stroke in 475 recently symptomatic pa
age.
Age Delay to CEA from most recent cerebral event
<2 days
(n ¼ 41)
3e7 days
(n ¼ 167)
60 years 0/10 (0.0%) 0/26 (0.0%)
61e79 years 1/24 (4.2%)CIS1 1/98 (1.0%)IOH1
80 years 0/7 (0.0%) 2/43 (4.7%)IOH2, CIS3
Overall 1/41 (2.4%) 3/167 (1.8%)
Note: Probable aetiology of peri-operative stroke is IOH1, IOH2, CIS1,hours, increasing to 8% at 7 days.2 More recently, a multi-
centre group has reported an 8% risk of stroke at 7 days in
TIA patients with a 50e99% carotid stenosis,19 with the
early risk being signiﬁcantly lower in patients who started
statin therapy as soon as they were seen.
In order to comply with NICE guidance, Leicester recon-
ﬁgured its stroke/TIA services in October 2008. Two
important components included a daily TIA clinic, led by
consultants in stroke medicine, and provision for a rapid-
access CEA service. A pilot study after the ﬁrst 100 pa-
tients suggested that expedited CEA was not associated
with increased procedural risks.5
However, despite enthusiasm for performing CEA as soon
as possible after onset of symptoms, there have been per-
sisting concerns that performing CEA in the hyperacute time
period may be associated with higher procedural risks to
the extent that any potential beneﬁt might be lost to the
patient. In 2006, Rockman et al.3 observed that patients
undergoing CEA within 28 days of presentation were
signiﬁcantly more likely to suffer a peri-operative stroke
than patients in whom >28 days had elapsed between
symptom and surgery (5.1% vs. 1.6%; p ¼ .002). This led
them to conclude that a delay to surgery might be beneﬁ-
cial. This debate then intensiﬁed following publication of
the 2012 SwedVasc Audit, which observed that patients
undergoing surgery within 48 hours of symptom onset
incurred an 11.5% risk of death/stroke. Interestingly, after
72 hours had elapsed, CEA was not associated with any
excess procedural risk. Patients undergoing CEA 3e7 days
after their index event had a 3.6% risk of death/stroke,
compared with 4% in patients undergoing CEA after 8e14
days and 5.4% in patients treated between 15e180 days.4
There are few comparable national audits that can either
refute or corroborate the Swedish experience. In July 2013,
the UK Department of Health published individual surgeon
and hospital data for CEA volumes, procedural risks and
delays to CEA.20 Out of 93 English hospitals, 57 (61%) re-
ported a median delay of <14 days between symptom and
undergoing surgery for the time period October 1, 2011, totients stratiﬁed for delay from most recent neurological event and
Total
(n ¼ 475)8e14
(n ¼ 133)
>14 days
(n ¼ 134)
0/26 (0.0%) 0/15 (0.0%) 0/77 (0.0%)
1/74 (1.4%)ICH 1/93 (1.1%)CIS2 4/289 (1.4%)
0/33 (0.00%) 0/26 (0.0%) 2/109 (1.8%)
1/133 (0.8%) 1/134 (0.8%) 6/475 (1.3%)
CIS2, CIS3, and ICH (see Table 2).
Table 4. Risk of early recurrent stroke in TIA patients with an ipsilateral 50e99% carotid stenosis.
First author Publication year Country of origin 48 hour 72 hour 7 days 14 days
Fairhead12 2005 UK 20%
Purroy13 2007 Spain 10%
Ois1 2009 Spain 17% 22% 25%
Johannson2 2012 Sweden 5% 8% 11%
Merwick19 2013 11 centres worldwide 8.3%
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median delay of 15e21 days; 13 (14%) had a median delay
of 22e28 days, while only three hospitals in England (3%)
reported median delays >28 days. Nine hospitals (10%)
reported a median delay of 7 days between symptom and
surgery. These nine hospitals performed 1,611 CEAs with a
30-day death/stroke rate of 2.7%.20 This level of risk is very
similar to that reported for SwedVasc patients undergoing
surgery between 3 and 7 days and also in the current audit
(Tables 2 and 3).
No UK data were, however, forthcoming regarding the
risk of CEA when performed <48 hours, but (in contrast to
the SwedVasc results), the data from the current audit did
not observe a signiﬁcant increase in procedural risk. In re-
ality (and evident from our own experience), relatively few
patients undergo surgery within such a short time frame,
but the vox populi interpretation of the SwedVasc data has
been to perhaps encourage an element of delay into the
patient pathway. While this might prove reasonable within
the ﬁrst 48 hours, such a policy would be inappropriate if it
unwittingly precipitated delays beyond this time period. In
essence, the desire to minimize risk by delaying surgery has
to be balanced with the increased risk of stroke immediately
after the index symptom (Table 4). It remains to be seen
whether starting aggressive medical therapy in the Clinic
(e.g. dual-antiplatelet and statin therapy) can signiﬁcantly
reduce the very high initial risk within the ﬁrst few days so
that CEA can be more safely deferred. In this respect, it is
perhaps appropriate to reﬂect upon an alternative analysis
of an individual patient meta-analysis of 6000þ patients
randomized within the European carotid Surgery Trial
(ECST), NASCET, and VA trials, which observed that a sur-
geon who operated within 2 weeks with a 10% procedural
risk would probably still prevent more strokes (in the long
term) than a surgeon who delayed intervening for 28 days
and then operated with a 0% risk.21 These randomized trial
data are now relatively historical (but they do emphasize
the beneﬁt of intervening early), but it is important to
acknowledge that they preceded awareness of the true
early risk of stroke after onset of symptoms in patients with
50e99% stenoses (Table 4). In reality, none of the land-
mark, randomized trials recruited and then treated many
patients within 7 days of symptom onset (never mind 48
hours). Accordingly; it may be that a 10% procedural risk
when CEA is performed within 48 hours of the index
symptom might actually be considered an acceptable de-
gree of risk. This controversial issue is currently being
evaluated in an Italian multicentre randomized trial.22
Finally, the current audit has shown that intervening in
the hyperacute period after onset of symptoms (whetherthis was deﬁned as <48 hours, <7 days, or <14 days)
was not associated with an excess procedural risk in pa-
tients who might otherwise be considered “high risk”
including patients presenting with a stroke and those
aged >80 years. The latter observation is important, as
pooled data from ECST and NASCET have shown that the
elderly symptomatic patient probably gains greater
beneﬁt from CEA than younger individuals. The absolute
risk reduction (ARR) conferred in recently symptomatic
patients aged <65 years who were randomized within
ECST and NASCET was 5.4% at 5 years, compared with
8.2% in patients aged 65e74 years and 16.9% in patients
aged 75.23
In summary; this audit has found no evidence that the
procedural risk increases when CEA is performed in the
hyperacute period after a recent TIA or non-disabling
stroke, including when performed in elderly patients. In a
recent review of 21 years of stroke prevention after CEA, we
attributed our very low procedural risks to an obsessional
attention to surgical technique, completion angioscopy/
intraoperative TCD, peri-operative dual antiplatelet therapy
and written guidelines for treating post-CEA hypertension.9
However, not included in the 21-year review (or the current
audit) were patients who suffered recurrent neurological
events in between admission to the Surgical Unit and un-
dergoing expedited CEA.
This was addressed in a recent audit, which observed an
11% risk of recurrent symptoms in the short time period
between admission to the Surgical Unit and expedited
CEA.24 This reafﬁrms just how high-risk this early time
period is. Most were TIAs, but two suffered disabling
strokes that prevented them from undergoing their CEA. To
date, we have been impressed with the beneﬁts of
administering clopidogrel (the night before surgery) in
preventing postoperative thromboembolic stroke. It re-
mains to be seen whether starting dual antiplatelet therapy
in the TIA clinic (rather than the night before surgery) and
then continuing this until surgery can prevent recurrent
events in the short period of time between admission and
surgery. This is the subject of an ongoing audit. A recently
published randomized trial in all TIA patients (i.e. not just
potential CEA patients) suggested that combination aspirin
and clopidogrel signiﬁcantly reduced the early risk of
recurrent stroke25 and such a strategy might be very
effective in the hyperacute period after onset of symptoms
in the future.FUNDING
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